期刊文献+

PET/CT检测冠状动脉旁路移植术患者存活心肌的研究进展 被引量:8

Research Progress of PET/CT Imaging for Detection of Viable Myocardium in Patients with Coronary Artery Bypass Grafting
下载PDF
导出
摘要 冠心病是威胁人类健康的主要疾病之一,并已开始在发展中国家蔓延。近年来,我国冠心病发病率有明显上升趋势,且呈年轻化发展,有效地控制冠心病发作,同时提高患者的生存质量是目前需要解决的关键问题。冠状动脉旁路移植术是严重冠心病患者重要而有效的治疗手段,但并非所有冠心病患者都能从中获益,许多临床证据均表明,只有在心肌存活的情况下,血运重建术才会发挥应有的效果,因此术前对于患者存活心肌的测定,是决定治疗方案,甚至是判断预后的关键因素之一。正电子发射型计算机断层显像/X线计算机断层是评价存活心肌的无创性影像手段之一,且被国际公认为判断存活心肌的"金标准"。 Coronary heart disease is one of the major health risks, the incidence of which has showed an upward trend in developing countries and age of onset is getting younger. Obviously, it is a key issue to reduce the morbidity effectively and improve quality of life for the patients. Coronary artery bypass grafting is an important and effective treatment in patients with severe coronary atherosclerotic heart disease. However, not all such patients will benefit from it. Lots of clinical evidences have shown that the surgery will be successful only when the myocardium are viable. Thus, the decisive factor of managing therapeutic scheme and predicting prognosis is the determination of viable myocardium. Positron emission computed tomography/x-ray computed tomography(PET/CT) is a noninvasive imaging modality for evaluating the viability of myocardium and is considered to be the "golden standard".
出处 《医学综述》 2017年第16期3291-3295,3301,共6页 Medical Recapitulate
基金 天津市卫生行业重点攻关项目(16KG145) 天津市滨海新区卫生计生委科技项目(2015BWKL002)
关键词 冠心病 冠状动脉旁路移植术 正电子发射计算机断层显像 存活心肌 Coronary heart disease Coronaryartery bypassgrafting Positron emission computed tomography/X-ray computed tomography Viable myocardium
  • 相关文献

参考文献4

二级参考文献57

  • 1Mittendorfer B, Liem O. What does the measure ment of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean[J]. Diabetes, 2003, 52:1 641-1 648.
  • 2Aarsland A, Chinkes D, Wolfe RR. Contributions of de novo synthesis of fatty acids to total VLDL- triglyceride secretion during prolonged hyperglyce- mia/hyperinsulinaemia in normal man[J]. J Clin Invest, 1996, 98:2 008-2 017.
  • 3Jalilian AR, Akhlaghi M, Mirzaii M, et al. Pro- duction and biological evaluation of [18 F]-6-thia- 14-fluoro-heptadecanoie acid [J].Nucl Med Rev Cent East Eur, 2006,9(2): 108-113.
  • 4Takala TO, Nuutila P, Pulkki K, et al. 14(R,S) [18F] Fluoro-6-thia-heptadecanoic acid as a tracer of free fatty acid uptake and oxidation in myocardi- um and skeletal muscle[J]. Eur J Nucl Med Mol Imaging, 2002, 29(12): 1 617-1 622.
  • 5Guiducci L, Gronroos T, Jarvisalo MJ, et al. Bio- distribution of the fatty acid analogue 18 F FTHA : plasma and tissue partitioning between lipid pools during fasting and hyperinsulinemia[J].J Nucl Med, 2007, 48(3): 455-462.
  • 6DeGrado TR, Kitapci MT, Wang S, et al. Valida- tion of 18F-fluoro-4-thia-palmitate as a PET probe for myocardial fatty acid oxidation: effects of hy- poxia and composition of exogenous fatty acids[J]. J Nucl Med, 2006, 47(1):173-181.
  • 7DeGrado TR, Bhattacharyya F, Pandey MK, et al. Synthesis and preliminary evaluation of 18 (18) F-fluoro 4-thia-oleate as a PET probe of fatty acid oxidation[J]. J Nucl Med, 2010, 51(8): 1 310-1 317.
  • 8Stone CK, Pooley RA, DeGrado TR, et al. Myo- cardial uptake of the fatty acid analog 14-fluorine 18-fluoro-6 thia-heptadecanoie acid in comparison to beta-oxidation rates by tritiated palmitate[J].J Nucl Med, 1998, 39(10): 1 690-1 696.
  • 9Schulz G, von DJ, Kaiser H J, et al. Imaging of beta-oxidation by static PET with 14 (R, S)-[18 F] fluoro-6-thiaheptadecanoic acid (FTHA) in pa- tients with advanced coronary heart disease: a comparison with 18SFDG-PET and 99Tcm-MIBI SPET[J]. Nucl Med Commun, 1996, 17(12): 1 057-1 064.
  • 10Taylor M, Wallhaus TR, Degrado TR, et al. An evaluation of myocardial fatty acid and glucose up- take using PET with [18 F] fluoro-6-thia-heptade- canoic acid and [18 F]FDG in Patients with Conges- tive Heart Failure[J]. J NuclMed, 2001, 42(1): 55 62.

共引文献101

同被引文献127

引证文献8

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部